Normal range is where most people land.It is not where you function best.

Normal range describes where most people your age and sex fall. It is a population statistic, not an individual target. Someone sitting at the bottom of a range can have meaningfully different energy, clarity, and recovery than the same person in the upper third. There is also the question of what was measured. A hormonal workup that captured TSH but not free T3, free T4, and reverse T3 has left out part of the thyroid picture. The question this program asks is not whether you are in range. It is where in that range you actually function.

The picture improved meaningfully in 2025. Following the TRAVERSE trial, the FDA removed cardiovascular-risk language from the Boxed Warning across all testosterone products. TRAVERSE enrolled 5,246 men with hypogonadism and existing or high cardiovascular risk, and found testosterone noninferior to placebo for major adverse cardiac events. Noninferior means not worse. It was designed to measure safety rather than to show a cardiac benefit. At the same time a new warning about increased blood pressure was added across all products, and the FDA retained its Limitation of Use language for age-related hypogonadism. Your care team reviews your full cardiovascular history and blood pressure before anything is prescribed, and tracks both throughout. Details are at FDA.gov.

Much of the older confusion traces to a single large study from the early 2000s whose findings were widely generalized beyond the population studied. Current published position guidance is considerably more nuanced. For women under sixty or within ten years of menopause onset, without contraindications, the benefit-risk balance is described as favorable for vasomotor symptoms and for maintaining bone density. Beyond that window it is described as less favorable because absolute risks rise. Risk also varies by type, dose, duration, route, and whether a progestogen is used. That is why guidance calls explicitly for individualized, shared decision-making, which is exactly how your program is run. The 2022 position statement is at PubMed.

It can, which is why fertility is planned for from the very first conversation. Testosterone given from outside suppresses the body’s own production of LH and FSH, which are required for sperm production. For men who have not completed their family, fertility-preserving alternatives exist, and your care team discusses which fit your situation before any protocol begins.

Because they are often the missing piece. Thyroid governs the metabolic rate at which every cell operates, and a workup that stops at TSH misses what the cells are actually receiving. Free T3, free T4, and reverse T3 tell that part of the story. Cortisol interacts closely with sex hormones. Reading all three together lets your protocol support the whole system, which is how you get the most from hormone therapy.

That depends on your goals and why you started. Where a genuine deficiency exists, replacement addresses an ongoing condition rather than a temporary one, and stopping generally returns you to where you began. For women, guidance recommends periodic reassessment of the benefit-risk balance rather than an indefinite continuation by default. Whatever the duration, your care team monitors throughout, with regular panels and reviews so your protocol keeps fitting you.

No. Valere operates as a private-pay practice. That is what allows the panel to be as comprehensive as it is, the time with your care team to be what it is, and the follow-up and coaching to be built in rather than billed for separately. An insurance-driven model would not support a ninety-minute assessment or a full thyroid and cortisol workup on someone whose TSH reads normal. Payment plans and membership options are available.